<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a retrospective analysis we assessed occurrence, contributing factors and outcome of patients experiencing granulocytic <z:hpo ids='HP_0100242'>sarcoma</z:hpo> as a localized extramedullary relapse after allogeneic BMT </plain></SENT>
<SENT sid="1" pm="."><plain>EBMT members were asked to report the number of patients transplanted for <z:hpo ids='HP_0001909'>leukemia</z:hpo> between January 1981 and December 1992 and the number of patients with granulocytic <z:hpo ids='HP_0100242'>sarcoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Of a total of 5824 patients transplanted for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, <z:mp ids='MP_0005481'>CML</z:mp> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> by 86 teams, granulocytic <z:hpo ids='HP_0100242'>sarcoma</z:hpo> was observed in 26 patients (0.45% occurring 4-56 months after BMT </plain></SENT>
<SENT sid="3" pm="."><plain>Granulocytic <z:hpo ids='HP_0100242'>sarcoma</z:hpo> occurred after allogeneic BMT in 20 out of 3071 patients grafted for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (0.65%), and in the <z:mp ids='MP_0005481'>CML</z:mp>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> subgroup in six out of 2753 grafted patients (0.22%) </plain></SENT>
<SENT sid="4" pm="."><plain>Granulocytic <z:hpo ids='HP_0100242'>sarcoma</z:hpo> can involve any site of the body, presenting as a soft tissue mass; it occurred in body cavities (eg pleural cavity, abdominal cavity, spinal canal, stomach and bladder), the head and neck region (orbit, ear, skull base, peripheral nerves), the trunk and limbs, and mammary and sex glands </plain></SENT>
<SENT sid="5" pm="."><plain>Granulocytic <z:hpo ids='HP_0100242'>sarcoma</z:hpo> predicts an additional hazard to outcome after BMT </plain></SENT>
<SENT sid="6" pm="."><plain>Nine of 26 patients (33%) were alive 15-151 months after the <z:hpo ids='HP_0003674'>onset</z:hpo> of granulocytic <z:hpo ids='HP_0100242'>sarcoma</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Advanced disease stage at grafting adversely affected survival and <z:hpo ids='HP_0000001'>all</z:hpo> patients died </plain></SENT>
<SENT sid="8" pm="."><plain>The best treatment option still needs to be defined </plain></SENT>
</text></document>